On July 18, Novo Nordisk announced that the National Medical Products Administration (NMPA) recently officially approved the new chronic kidney disease (CKD) indication for Novotec (semaglutide injection), making it the first and only GLP-1 receptor agonist (GLP-1RA) in China approved to reduce the risk of continued decline in eGFR, end-stage renal disease and cardiovascular death in adult patients with type 2 diabetes and chronic kidney disease.